Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.

FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.

Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.

US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.